Evidence map›Paper›PMID 34629923›Full record

ArticleClinical Medicine Insights. Oncology2021

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma.

Shogo Shinohara, Shinji Takebayashi, Kiyomi Hamaguchi, Tetsuhiko Michida, Yota Tobe, Tadashi Ikenaga, Mami Yasumoto, Ayami Hamamoto, Toshiyuki Imagumbai, Takamasa Mitsuyoshi and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Shogo ShinoharaDepartment of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.ORCID https://orcid.org/0000-0002-1794-2091
Shinji TakebayashiDepartment of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Kiyomi HamaguchiDepartment of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Tetsuhiko MichidaDepartment of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Yota TobeDepartment of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Tadashi IkenagaDepartment of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Mami YasumotoDepartment of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Ayami HamamotoDepartment of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Toshiyuki ImagumbaiDepartment of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Takamasa MitsuyoshiDepartment of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Ryo AshidaDepartment of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Takahiro IwaiDepartment of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Shun OkabayashiDepartment of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Kobe City Medical Center General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConcurrent chemoradiotherapy (CCRT) with tri-weekly high-dose cisplatin (HDC) is considered the standard regimen. However, due to significant toxicity, various weekly low-dose schedules have been increasingly used. We investigated the tolerability and survival of patients with head and neck squamous cell carcinoma (HNSCC) who underwent CCRT with low-dose weekly cisplatin (LDC) for Japanese population.

methodsA retrospective review was conducted among patients with HNSCC who were treated with CCRT/LDC in our institute. Ninety-five patients who met the criteria were enrolled in this study. We evaluated the cycle and cumulative cisplatin dose, completion rate of radiotherapy, adverse events, and survival outcome.

resultsThe mean cycles and cumulative cisplatin dose were 4.7 cycles and 187 mg/m

conclusionsConcurrent chemoradiotherapy/LDC can be safely administered with acceptable toxicity and survival outcome even if the patients with higher age, lower eGFR, and so on.

Indexed as

chemoradiotherapiescisplatinconcomitantHead and neck cancer

Identifiers

PMID34629923
PMCPMC8493312
OpenAlexW3207107549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.